Literature DB >> 19897577

CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.

Jianhua Yu1, Hsiaoyin C Mao, Min Wei, Tiffany Hughes, Jianying Zhang, Il-kyoo Park, Shujun Liu, Susan McClory, Guido Marcucci, Rossana Trotta, Michael A Caligiuri.   

Abstract

Human CD56(bright) natural killer (NK) cells possess little or no killer immunoglobulin-like receptors (KIRs), high interferon-gamma (IFN-gamma) production, but little cytotoxicity. CD56(dim) NK cells have high KIR expression, produce little IFN-gamma, yet display high cytotoxicity. We hypothesized that, if human NK maturation progresses from a CD56(bright) to a CD56(dim) phenotype, an intermediary NK cell must exist, which demonstrates more functional overlap than these 2 subsets, and we used CD94 expression to test our hypothesis. CD94(high)CD56(dim) NK cells express CD62L, CD2, and KIR at levels between CD56(bright) and CD94(low)CD56(dim) NK cells. CD94(high)CD56(dim) NK cells produce less monokine-induced IFN-gamma than CD56(bright) NK cells but much more than CD94(low)CD56(dim) NK cells because of differential interleukin-12-mediated STAT4 phosphorylation. CD94(high)CD56(dim) NK cells possess a higher level of granzyme B and perforin expression and CD94-mediated redirected killing than CD56(bright) NK cells but lower than CD94(low)CD56(dim) NK cells. Collectively, our data suggest that the density of CD94 surface expression on CD56(dim) NK cells identifies a functional and likely developmental intermediary between CD56(bright) and CD94(low)CD56(dim) NK cells. This supports the notion that, in vivo, human CD56(bright) NK cells progress through a continuum of differentiation that ends with a CD94(low)CD56(dim) phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897577      PMCID: PMC2808153          DOI: 10.1182/blood-2009-04-215491

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

1.  CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity.

Authors:  Yoshihiro Hayakawa; Mark J Smyth
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

2.  Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin.

Authors:  Carmelo Luci; Ana Reynders; Ivaylo I Ivanov; Celine Cognet; Laurent Chiche; Lionel Chasson; Jean Hardwigsen; Esperanza Anguiano; Jacques Banchereau; Damien Chaussabel; Marc Dalod; Dan R Littman; Eric Vivier; Elena Tomasello
Journal:  Nat Immunol       Date:  2008-11-23       Impact factor: 25.606

3.  Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily.

Authors:  C Chang; A Rodríguez; M Carretero; M López-Botet; J H Phillips; L L Lanier
Journal:  Eur J Immunol       Date:  1995-09       Impact factor: 5.532

4.  Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.

Authors:  Jianhua Yu; Min Wei; Brian Becknell; Rossana Trotta; Shujun Liu; Zachary Boyd; Michael S Jaung; Bradley W Blaser; Jin Sun; Don M Benson; Hsiaoyin Mao; Akihiko Yokohama; Darshna Bhatt; Lei Shen; Ramana Davuluri; Michael Weinstein; Guido Marcucci; Michael A Caligiuri
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

Review 5.  Regulation of interferon-gamma during innate and adaptive immune responses.

Authors:  Jamie R Schoenborn; Christopher B Wilson
Journal:  Adv Immunol       Date:  2007       Impact factor: 3.543

6.  Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense.

Authors:  Naoko Satoh-Takayama; Christian A J Vosshenrich; Sarah Lesjean-Pottier; Shinichiro Sawa; Matthias Lochner; Frederique Rattis; Jean-Jacques Mention; Kader Thiam; Nadine Cerf-Bensussan; Ofer Mandelboim; Gerard Eberl; James P Di Santo
Journal:  Immunity       Date:  2008-12-11       Impact factor: 31.745

7.  Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.

Authors:  M Frey; N B Packianathan; T A Fehniger; M E Ross; W C Wang; C C Stewart; M A Caligiuri; S S Evans
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

Review 8.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

Review 9.  Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4.

Authors:  Wendy T Watford; Bruce D Hissong; Jay H Bream; Yuka Kanno; Linda Muul; John J O'Shea
Journal:  Immunol Rev       Date:  2004-12       Impact factor: 12.988

10.  Evidence for discrete stages of human natural killer cell differentiation in vivo.

Authors:  Aharon G Freud; Akihiko Yokohama; Brian Becknell; Melissa T Lee; Hsiaoyin C Mao; Amy K Ferketich; Michael A Caligiuri
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

View more
  112 in total

Review 1.  NK cell trafficking in health and autoimmunity:a comprehensive review.

Authors:  Hui Peng; Zhigang Tian
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 2.  DCs and NK cells: critical effectors in the immune response to HIV-1.

Authors:  Marcus Altfeld; Lena Fadda; Davor Frleta; Nina Bhardwaj
Journal:  Nat Rev Immunol       Date:  2011-03       Impact factor: 53.106

3.  Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells.

Authors:  Isabell Hamann; Nadine Unterwalder; Astrid E Cardona; Christian Meisel; Frauke Zipp; Richard M Ransohoff; Carmen Infante-Duarte
Journal:  Immunology       Date:  2011-02-14       Impact factor: 7.397

4.  Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in mice.

Authors:  Ren Zhu; Maryline Mancini-Bourgine; Xiao Ming Zhang; Florence Bayard; Qiang Deng; Marie-Louise Michel
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

5.  Alterations of natural killer cells in traumatic brain injury.

Authors:  Xiao-Dong Kong; Sheng Bai; Xin Chen; Hui-Jie Wei; Wei-Na Jin; Min-Shu Li; Yaping Yan; Fu-Dong Shi
Journal:  Neurosci Bull       Date:  2014-12-02       Impact factor: 5.203

6.  Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function.

Authors:  Youcai Deng; Yann Kerdiles; Jianhong Chu; Shunzong Yuan; Youwei Wang; Xilin Chen; Hsiaoyin Mao; Lingling Zhang; Jianying Zhang; Tiffany Hughes; Yafei Deng; Qi Zhang; Fangjie Wang; Xianghong Zou; Chang-Gong Liu; Aharon G Freud; Xiaohui Li; Michael A Caligiuri; Eric Vivier; Jianhua Yu
Journal:  Immunity       Date:  2015-03-10       Impact factor: 31.745

7.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

Review 8.  Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience.

Authors:  Knut Liseth; Elisabeth Ersvaer; Tor Hervig; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2010-06-02

9.  NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs.

Authors:  Vivien Béziat; Benjamin Descours; Christophe Parizot; Patrice Debré; Vincent Vieillard
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

10.  Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Authors:  Alexander Vargas-Hernández; Emily M Mace; Ofer Zimmerman; Christa S Zerbe; Alexandra F Freeman; Sergio Rosenzweig; Jennifer W Leiding; Troy Torgerson; Matthew C Altman; Edith Schussler; Charlotte Cunningham-Rundles; Ivan K Chinn; Alexandre F Carisey; Imelda C Hanson; Nicholas L Rider; Steven M Holland; Jordan S Orange; Lisa R Forbes
Journal:  J Allergy Clin Immunol       Date:  2017-10-27       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.